Clinical Trial Update: Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study [Phase 4]

View source ↗

Summary

Phase 4 trial update on bosentan for pulmonary hypertension in interstitial lung disease; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Nonspecific Interstitial Pneumonia
• Pulmonary Hypertension

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Royal Brompton & Harefield NHS Foundation Trust | Conditions: Pulmonary Hypertension, Interstitial Lung Disease | Phase 4 | Status: UNKNOWN